This paper evaluates the practice of microdosing tirzepatide from multi-dose pens — using sub-standard doses drawn from shared or reused pen cartridges — focusing on clinical individualization rationale, safety concerns, and gaps in the evidence base.
No primary clinical trial data are reported; the paper identifies that microdosing lacks regulatory approval and controlled evidence, while acknowledging its use for tolerability management and cost mitigation, with unresolved safety signals around sterility, dosing accuracy, and pharmacokinetics.
No original clinical data or controlled comparisons are presented; conclusions rest on expert opinion and indirect evidence. Real-world microdosing practices are heterogeneous and poorly characterized. Long-term outcomes and adverse event rates from microdosing are unknown.
Clinicians should be aware that microdosing tirzepatide from multi-dose pens is practiced off-label for tolerability and cost reasons, but lacks safety and efficacy data — patients doing this should be counseled on sterility risks, dosing inaccuracy, and the absence of regulatory guidance.
Explore related topics
